利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

69 条记录 (耗时 0.018 秒)

    HUMAN ANTIBODIES TO PD-1
    35.
    发明公开
    HUMAN ANTIBODIES TO PD-1 审中-公开

    公开(公告)号：EP3967710A1

    公开(公告)日：2022-03-16

    申请号：EP21185778.4

    申请日：2015-01-23

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： PAPADOPOULOS, Nicholas, J. ,  MURPHY, Andrew, J. ,  THURSTON, Gavin ,  IOFFE, Ella ,  BUROVA, Elena

    IPC分类号： C07K16/28

    摘要： The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.

    ANTIBODY COMPOSITIONS FOR TUMOR TREATMENT
    36.
    发明公开
    ANTIBODY COMPOSITIONS FOR TUMOR TREATMENT 审中-公开

    公开(公告)号：EP3848395A1

    公开(公告)日：2021-07-14

    申请号：EP21151864.2

    申请日：2015-03-18

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： DAVIS, Samuel ,  SMITH, Eric ,  VARGHESE, Bindu ,  KIRSHNER, Jessica R. ,  THURSTON, Gavin

    IPC分类号： C07K16/28 ,  A61K39/395

    摘要： The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fcy receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fcy receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.

    HUMAN ANTIBODIES TO PD-L1
    39.
    发明公开
    HUMAN ANTIBODIES TO PD-L1 审中-公开

    公开(公告)号：EP3473648A1

    公开(公告)日：2019-04-24

    申请号：EP18206830.4

    申请日：2015-01-23

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： PAPADOPOULOS, Nicholas, J. ,  MURPHY, Andrew, J. ,  THURSTON, Gavin ,  IOFFE, Ella ,  BUROVA, Elena

    IPC分类号： C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  C07K16/22 ,  A61P35/00 ,  A61K39/00

    摘要： The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligandl (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.